Study wrapper · #1185
Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis.
Editor's note
This large claims analysis puts real-world numbers on tirzepatide persistence: 68 percent of initiators stayed on therapy through six months, better than figures often reported for the GLP-1 class. The 10.5 percent average weight reduction among persistent users tracks reasonably close to trial results, though it comes from only 808 people with usable before-and-after weights — a small, possibly unrepresentative slice. Worth noting the author list includes Eli Lilly-affiliated researchers, standard for this kind of manufacturer-sponsored database work.
Plain-language abstract
Among 22,512 commercially insured US adults who started tirzepatide for weight management, about two-thirds were still on it at six months, and those who stayed on lost an average of 10.5 percent of their body weight — 12 percent for people new to GLP-1 drugs.